hotspot -WSS

hotspot

author：knowledge 2025-09-28 20:32:45 - browse：72766

To much of the public, the promise of telehealth is all about convenience — get the prescription you need quickly, and get it delivered right to your door. But as digital health companies build out their weight loss businesses, capitalizing on the popularity of drugs like Wegovy and Ozempic, they’re courting a very different audience: payers and employers who have a vested interest in preventing quick scripts.

Payers are reeling as they try to figure out how to sustainably cover GLP-1 receptor agonists, a class of remarkably effective but expensive obesity and type 2 diabetes drugs. So in the last six months, digital health companies including Teladoc, Found, Hello Alpha, and Calibrate have advanced enterprise products that pair virtual visits and prescriptions with lifestyle coaching. Their hope is that more and more payers and employers will offer their programs as a way to support lasting weight loss and metabolic health — or even require them if patients want their drugs reimbursed.

The competition is growing quickly. Telehealth companies once focused exclusively on consumers are now marketing to payers. Enterprise programs for chronic care management are promoting new services to support patients on obesity drugs. And companies like Noom and WeightWatchers, which have built gargantuan weight loss businesses for consumers and businesses alike, are starting to prescribe the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Merck, Johnson & Johnson CEOs will testify on high drug prices

hotspot

leisure time

WSS

Abortion pill Supreme Court ruling could impact entire drug industry

Study says nonprofit hospitals fall short in charity care spending

Vertex non

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Syphilis numbers in the United States reach record heights

Reconstructing family trees of blood cells may help predict disease

focus

hotspot

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

Study says nonprofit hospitals fall short in charity care spending

Trump demands the U.S. pay no more for drugs than other countries … again

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Hollywood unions extend contract negotiations for actors

Covid vaccine financial winners and losers, from Pfizer to Novavax

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Primary care physicians play key roles in Alzheimer's management

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Patient advocates debate FDA's accelerated approval process

explore

Abortion pill Supreme Court ruling could impact entire drug industry

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Merck drug for rare lung condition set for approval in U.S.

Humana’s losses in Medicare Advantage tank its stock

The Affordable Care Act has saved billions in health care costs

hotspot

knowledge

leisure time

entertainment